Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

KV Pharmaceutical Enters Into Consent Decree With FDA

By Pharmaceutical Processing | March 2, 2009

KV Pharmaceutical Company has entered into a consent decree withthe FDA regarding the company’s drugmanufacturing and distribution. The decree provides a series of measuresthat, when satisfied, will permit KV to resume the manufacture anddistribution of products marketed by its subsidiaries, ETHEX and Ther-Rx. TheCompany is working expeditiously to satisfy the requirements and expects toprovide further information in upcoming communications. As part of the consent decree, KV has agreed not to market products itmanufactures until it has satisfied certain requirements designed todemonstrate compliance with FDA’s current good manufacturing practices (CGMP)regulations. KV has also agreed that it will not distribute certain products,including its prenatal vitamins and hematinic products, until the products areapproved by FDA’s ANDA or NDA processes. “We have been working diligently with the FDA for the last two months toreach agreement on a clear path forward to permit KV to resume manufacturingand marketing its products,” said David A. Van Vliet, KV’s Interim ChiefExecutive Officer. “Since December, when new management took over at KV, ourteam has taken significant steps to enhance our systems and procedures, and wewill continue to do so. We look forward to cooperating with the FDA duringthis process that will facilitate our return to the market. Predicting thetiming for the return and the ultimate product assortment that we will marketare presently very difficult due to the range of variables that must bemanaged. As we gain certainty, we will notify customers and all otherstakeholders.” The consent decree provides that, before resuming manufacturing, KV willhave an independent third party CGMP expert consultant undertake a review ofKV’s facilities and certify compliance with FDA’s CGMP regulations. Followingthat certification, FDA will make a determination as to whether the KVfacilities are in compliance. The decree further provides that KV may requestof FDA that it be permitted to resume manufacturing and distribution ofcertain products before the company is cleared by FDA to resume fulloperations. KV has already retained the third party CGMP expert consultant,which has been on-site for several weeks. The consent decree is expected to be submitted today to the U.S. DistrictCourt, Eastern District of Missouri, Eastern Division by the Department ofJustice and is subject to approval by the Court.

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards